[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631983":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":67,"collaborators":69,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":20,"enrollmentInfo":85,"targetDuration":20,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Centre Oscar Lambret","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant radiotherapy","EXPERIMENTAL","Neoadjuvant radiotherapy as described in the \"intervention description\" field, followed by a tumor resection 4 to 8 after the last session of radiotherapy.",[13],"Radiation: Moderately hypofractionated neoadjuvant radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Moderately hypofractionated neoadjuvant radiotherapy","Intensity-modulated radiotherapy with a moderately hypofractionated scheme consisting of 15 fractions of 2.7 Gy administered over 3 weeks.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Abel CORDOBA, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Julien THERY","CONTACT","(0)320295918","+33","promotion@o-lambret.fr",[33],{"facility":5,"status":34,"city":35,"state":20,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Lille","59000","France","FR",{"type":40,"coordinates":41},"Point",[42,43],3.05512,50.63391,{"lat":43,"lon":42},[46,49,50,53,55,57,59,61,63,65],{"name":23,"role":28,"phone":47,"phoneExt":20,"email":48},"+33(0)20295920","a-cordoba@o-lambret.fr",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":51,"role":52,"phone":20,"phoneExt":20,"email":20},"Pauline LEMOINE-GOBERT, MD","SUB_INVESTIGATOR",{"name":54,"role":52,"phone":20,"phoneExt":20,"email":20},"Isaure ROQUETTE, MD",{"name":56,"role":52,"phone":20,"phoneExt":20,"email":20},"Mehrad JAFARI, MD",{"name":58,"role":52,"phone":20,"phoneExt":20,"email":20},"Gauthier DECANTER, MD",{"name":60,"role":52,"phone":20,"phoneExt":20,"email":20},"Antoine CAYEUX, MD",{"name":62,"role":52,"phone":20,"phoneExt":20,"email":20},"Justine KHDOR, MD",{"name":64,"role":52,"phone":20,"phoneExt":20,"email":20},"Thomas RYCKEWAERT, MD",{"name":66,"role":52,"phone":20,"phoneExt":20,"email":20},"Loïc LEBELLEC, MD",{"type":68,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[70,73],{"name":71,"class":72},"Canther, Lille","UNKNOWN",{"name":74,"class":72},"Centre de traitement des données du Cancéropôle Nord-Ouest, Centre F. BACLESSE, Caen, France","100631983","phase-2-assessment-of-the-long-term-efficacy-of-moderately-hypofractionated-neoadjuvant-radiotherapy-soft-tissue-sarcoma-in-the-limbs-or-trunk-wall-100631983",false,"NCT07507773","Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall","Phase II Clinical Trial Assessing the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall, Incorporating Translationnal Research","NEORASARC","Inclusion Criteria:\n\n* Patient aged ≥ 18 years ;\n* Localised sarcoma of a limb, the root of a limb, or the trunk wall ;\n* Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ;\n* Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ;\n* Indication of neoadjuvant radiotherapy according to the multidisciplinary consultation meeting ;\n* Tumor considered operable with a curative intent and conservative intent according to the multidisciplinary consultation meeting ;\n* Affiliation to the French National Social Security System ;\n* Informed and signed consent\n\nExclusion Criteria:\n\n* Metastatic disease (including local lymph node diffusion) ;\n* Visceral or retroperitoneal sarcoma ;\n* Tumor considered inoperable even after radiotherapy, according to the multidisciplinary consultation meeting ;\n* Indication of neoadjuvant or adjuvant chemotherapy ;\n* Ewing tumor of soft tissue, desmoid tumor, embryonal or alveolar rhabdomyosarcoma ;\n* Pregnant or breastfeeding women ;\n* Patients under protective measures ;\n* Patient refusal.","ALL","18 Years",{"count":86,"type":87},135,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall. The primary outcome is local disease control, assessed by the cumulative incidence of progression\u002Frecurrence.\n\nAfter informed consent has been obtained and eligibility criteria have been checked, a baseline assessment will be performed followed by the experimental treatment: intensity-modulated radiotherapy with a moderately hypofractionated regimen consisting in 15 fractions of 2.7 Gy administered over 3 weeks.\n\na follow-up assessment will be performed 3 to 4 weeks after the last radiotherapy session.\n\nTumor resection will be performed 4 to 8 weeks after the radiotherapy. Patients will then be followed up until the end of the study; planned 5 years after the last inclusion.\n\nRadiotherapy will be evaluated in terms of safety and efficacy.",[93,94,95,96],"Soft Tissue Sarcoma Adult","Soft Tissue Sarcoma (Excluding GIST)","Soft Tissue Sarcoma of the Trunk and Extremities","Soft Tissue Sarcoma of the Limb",[98,99,100,101,102],"Sarcoma","Trunk","Limb","Radiotherapy","Neoadjuvant","2026-06-18",{"date":105,"type":106},"2026-06-22","ACTUAL",{"date":108,"type":87},"2026-06-01",{"date":110,"type":87},"2035-06-01",{"name":5,"class":6},1]